
    
      An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the
      Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects when Administered Alone
      and in Combination with Fostamatinib 100 mg Twice Daily.
    
  